Entries by Mediplus Pharma
Mediplus Pharma is presenting posters at Society for Investigative Dermatology（SID）annual meeting 2022
Mediplus Pharma, Inc. (CEO: Kenji Ito, Head Office: Shibuya-ku, Tokyo,JAPAN) made a scientific presentation at the annual meeting of the Society for Investigative Dermatology (May 18-21, 2022, Portland, USA), which is considered the world’s highest-level society in dermatological research. Title：Novel glycerin compounds improve skin health
New ways to reduce facial age spots. Japanese Pharmaceutical R&D company Mediplus Pharma found the new ability of “High performance Glycerin” Effective in 92% of people after 8 weeks of continuous use.
FOR IMMEDIATE RELEASE Mediplus Pharma, Inc. (CEO: Kenji Ito, Head Office: Shibuya-ku, Tokyo,JAPAN) confirmed that cosmetics containing its patented ingredient, high performance ozonized glycerin, have the effect of reducing melanin (age spots) in the epidermis, and filed a new application patent which claimed melanin decomposition.
The Effect of Ozone Gel on Bone Matrix Production by Human Osteosarcoma Cell Line Saos-2
Pao-Li Wang1)*, Yoichi Tachi2)*, Kazuya Masuno1), Nobutaka Okusa3) and Yasuhiro Imamura4)1) Department of Innovation in Dental Education, Osaka Dental University, Osaka, Japan2) Laboratory of Nutritional Physiology, Tokyo Kasei University, Tokyo, Japan3) Department of Forensic Dentistry, Osaka Dental University, Osaka, Japan4) Department of Dental Pharmacology, Matsumoto Dental University, Shiojiri, Japan(Accepted for publication, April 20, 2018) Abstract Ozone is currently being considered […]
The 36th Japanese Nursing Association Compendium: “Deodorization effects of ozone products against unpleasant cancer odor.”
Abstract: The last stage of a human life is a crucial period for people and their family. Various approaches are being used to study the way people want to spend their last moments, including palliative care. In this study, we succeeded in drastically reducing the unpleasant cancer odor of a patient who had long been bothered by it by using […]